Published February 27, 2025 | Version v1
Journal article Open

Multimorbid Patient with Early Gout: Efficacy and Safety of Urate-lowering Treatment

Authors/Creators

  • 1. Shupyk National Healthcare University of Ukraine, Ukraine

Description

Patients with gout and hyperuricemia (GU) have a higher frequency of comorbid diseases compared to the age-related population indicator, which may affect the effectiveness and safety of using medical drugs for the treatment of GU.

The objective: to analyze the effectiveness and safety of using various urate-lowering therapy (ULT) drugs in the treatment of patients with newly diagnosed gout on the background of concomitant diseases in real medical practice.

Materials and methods. The study included 112 patients aged 37 to 62 years, who were first diagnosed with gout with a duration of pain syndrome of up to 3 months. The study was conducted at the Department of Therapy, Family Medicine, Hematology and Transfusiology of the Shupyk National Healthcare University of Ukraine on the basis of the Kyiv Regional Clinical Hospital in 2024.

All patients underwent a complex of clinical, laboratory and instrumental examinations, and medical cards were analyzed to identify concomitant diseases. The study participants were divided into two comparable groups of 56 persons each. The patients in the 1st group were prescribed febuxostat, and patients in the 2nd group were prescribed allopurinol. Regardless of the selected ULT drug, all patients were prescribed anti-inflammatory therapy.

Results. According to the results of the initial examination and medical documentation, comorbid diseases were detected in all patients, namely: 64.08% persons were diagnosed with arterial hypertension, 63.19% – dyslipidemia, 61.4% –overweight or obesity, 54.29% – metabolic-associated fatty liver disease, 52.51% – osteoarthritis, 36.49% – digestive tract diseases, 18.69% – ischemic heart disease, 15.13% – prediabetes or type 2 diabetes mellitus, and 15.13% – urolithiasis. The average number of identified comorbid pathologies per patient was 4.28 ± 0.14.

Analysis of the effectiveness and safety of the use of ULT drugs in the treatment of the studied multimorbid patients over the next 6 months demonstrated the higher effectiveness in patients of the 1st group who took febuxostat with the same level of determined adverse events in both groups.

Conclusions. During the study, it was found that patients with early gout have a significant number of concomitant pathological conditions and diseases. The increased levels of hepatic transaminases in the blood serum during treatment in patients of both groups was more often in persons with concomitant metabolic-associated fatty liver disease. Determining the impact of comorbid pathology and its pharmacotherapy on the success of gout treatment and the development of adverse events requires further research.

Other

https://family-medicine.com.ua/article/view/324240

Files

Multimorbid_Patient_with_Early_Gout_Efficacy_and_Safety_of_Urate_lowering_Treatment.pdf

Files (2.1 MB)

Additional details

References

  • GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990–2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024;(6):507–17.
  • Timsans J, Kauppi JE, Kerola AM, Lehto TM, Kautiainen H, Kauppi MJ. Hyperuricaemia: prevalence and association with mortality in an elderly Finnish population. BMJ Open. 2023;13(5):e072110. doi: 10.1136/bmjopen-2023-072110.
  • Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, et al. The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years. J Rheumatol. 2018;45(4):574–9. doi: 10.3899/jrheum.170806.
  • Hisatome I, Ichida K, Mineo I, Ohtahara A, Ogino K. Japanese Society of Gout and Uric & Nucleic Acids 2019 guidelines for management of hyperuricemia and gout. Gout Uric Nucleic Acids. 2020;44:40.
  • Russell MD, Rutherford AI, Ellis B, Norton S, Douiri A, Gulliford MC, et al. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom. Lancet Reg Health Eur. 2022;18:100416. doi: 10.1016/j.lanepe.2022.100416.
  • FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, AbelesAM, et al. American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60. doi: 10.1002/acr.24180.
  • Lai SW, Liao KF, Hwang BF, Liu CS. Real-world treatment of gout and asymptomatic hyperuricaemia in Japan. Mod Rheumatol. 2023;34(1):245–6. doi: 10.1093/mr/road006.
  • Smiyan SI, Makhovska OYu. Uncontrolled gout as a possible cause of comorbidity and a risk factor for a severe COVID-19 course. Ukr Rheumatol J. 2022;87(1):1–8. doi: 10.32471/rheumatology.2707-6970.87.16902.
  • Li D, Wang D, Dai X, Ni Y, Xu X. Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: A prospective cohort study. Front Public Health. 2022;(10):1012223. doi: 10.3389/fpubh.2022.1012223.
  • King C, Lanaspa MA, Jensen T, Tolan DR, Sánchez-Lozada LG, Johnson RJ. Uric acid as a cause of the metabolic syndrome. Contrib Nephrol. 2018;192:88–102. doi: 10.1159/000484283.
  • Katsiki N, Papanas N, Fonseca VA, Maltezos E, Mikhailidis DP. Uric acid and diabetes: is there a link? Curr Pharm Des. 2013;19:4930–7. doi: 10.2174/1381612811319270016.
  • Sakata S, Hata J, Honda T, Hirakawa Y, Oishi E, Shibata M, et al. Serum uric acid levels and cardiovascular mortality in a general Japanese population: the Hisayama Study. Hypertens Res. 2020;43:560–8. doi: 10.1038/s41440-019-0390-8.
  • Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, et al. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol. 2006;17(4):69–73. doi: 10.1681/ASN.2005121331.
  • Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150–63. doi: 10.1016/j.cca.2018.05.046.
  • Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7–13. doi: 10.7326/0003-4819-131-1-199907060-00003.
  • Timsans J, Palomäki A, Kauppi M. Gout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications. J Clin Med. 2024;13(24):7616. doi: 10.3390/jcm13247616.
  • Rai SK, Choi HK, Choi SHJ, Townsend AF, Shojania K, De Vera MA. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford). 2018;57(7):1282–92. doi: 10.1093/rheumatology/kex530.
  • Guo Y, Huang H, Chen Y, Shen C, Xu C. Association between circulating cystatin C and hyperuricemia: a cross-sectional study. Clin Rheumatol. 2022;41(7):2143–51. doi: 10.1007/s10067-022-06139-6.
  • Akashi N, Kuwabara M, Matoba T, Kohro T, Oba Y, Kabutoya T, et al. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan. Front Cardiovasc Med. 2023;9:1062894. doi: 10.3389/fcvm.2022.1062894.
  • Liu L, Zhao T, Shan L, Cao L, Zhu X, Xue Y. Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway. Nutr Metab (Lond). 2021;18(1):63. doi: 10.1186/s12986-021-00583-y.
  • Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, et al. Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension. 2020;75(2):302–08. doi: 10.1161/HYPERTENSIONAHA.119.13643.
  • Cang Y, Xu S, Zhang J, Ju J, Chen Z, Wang K, et al. Serum Uric Acid Revealed a U-Shaped Relationship With All-Cause Mortality and Cardiovascular Mortality in High Atherosclerosis Risk Patients: The ASSURE Study. Front Cardiovasc Med. 2021;8:641513. doi: 10.3389/fcvm.2021.641513.
  • Masulli M, D'Elia L, Angeli E, Esposito D, Vaccaro O, Giugliano D, et al. Uric acid as a risk factor for cardiovascular disease and mortality in individuals with type 2 diabetes. Nutrient. 2023;15:394.
  • Kikuchi A, Kawamoto R, Ninomiya D, Kumagi T. Hyperuricemia is associated with all cause mortality among males and females: Findings from a study on Japanese community-dwelling individuals. Metabol Open. 2022;14:100186. doi: 10.1016/j.metop.2022.100186.
  • Timsans J, Kauppi JE, Kerola AM, Lehto TM, Kautiainen HJ, Kauppi MJ. Hyperuricaemia-associated all-cause mortality risk effect is increased by non-impaired kidney function – Is renal hyperuricaemia less dangerous? Eur J Intern Med. 2024;121:56–62. doi: 10.1016/j.ejim.2023.10.009.
  • Timsans J, Kerola AM, Rantalaiho VM, Hakkarainen KN, Kautiainen HJ, Kauppi MJ. «Metabolic» Type of Hyperuricemia Increases Mortality Mainly by Leading to Premature Death From Cardiovascular Disease. Mayo Clin Proc. 2024;99(11):1835–7. doi: 10.1016/j.mayocp.2024.07.011.